CJC-1295 (no DAC) + Ipamorelin Blend · 5mg / 5mg · Research Peptide

Compound Profile

Two compounds. One vial. Full traceability.

Each blend vial ships with structural data and lot identifiers for both peptides, plus a single Certificate of Analysis documenting per-component purity and the blended composition.

Pre-mixed for the bench.

Both peptides are synthesized via solid-phase peptide chemistry, purified independently by reverse-phase HPLC, and combined in a single vial at a verified 5mg / 5mg ratio. Mass spectrometry confirms identity for each component, and sterility plus endotoxin testing applies to the final blend.

View signed COA

— Component 01

CJC-1295 · 5mg

Class

GHRH analog (30-AA)

Sequence

Mod GRF (1-29) · D-Ala²-Gln⁸-Ala¹⁵-Leu²⁷

CAS Number

446262-90-4

Molecular Formula

C₁₅₂H₂₅₂N₄₄O₄₂

Molecular Weight

3367.9 g/mol

Per-component purity

≥ 99%

— Component 02

Ipamorelin · 5mg

Class

Selective GH secretagogue

Sequence

Aib-His-D-2Nal-D-Phe-Lys-NH₂

CAS Number

170851-70-4

Molecular Formula

C₃₈H₄₉N₉O₅

Molecular Weight

711.85 g/mol

Per-component purity

≥ 99%

— Blend

Combined Vial

Total content

10 mg total · 5mg + 5mg

Form

White powder, single vial

Identity (LC-MS)

Both confirmed

Sterility / LAL

PASS

Storage

2-8°C, sealed, dry

Origin

Made in the USA

In the Literature

Two compounds, two research records.

A short, sourced summary of where each compound appears in the published research record. For context only. Not a claim, not a protocol, not advice.

CJC-1295 (no DAC), also known as Modified GRF (1-29) or Mod GRF (1-29), is a synthetic 30-amino-acid analog of the first 29 residues of human growth hormone-releasing hormone (hGRF 1-29) with four amino acid substitutions for stability. Unlike the long-acting CJC-1295 (with DAC), the no-DAC variant lacks the maleimide-lysine conjugation that binds serum albumin, giving it a shorter half-life that more closely mimics native GHRH pulsatility.

Ipamorelin is a synthetic pentapeptide developed in the late 1990s as a selective growth hormone secretagogue in the GHRP family. It binds the ghrelin receptor (GHSR1a) to stimulate pulsatile GH release without the cortisol or prolactin elevation observed with earlier-generation secretagogues such as GHRP-6.

Both compounds are most-cited alongside investigations of angiogenesis, actin cytoskeletal remodeling, and tissue regeneration pathways in animal models. Neither has been approved by the FDA for any therapeutic indication. Both remain classified as research compounds.

For research use only. Statements above describe published research literature and do not constitute health, medical, or therapeutic claims for either compound or for the blend. Not for human or veterinary use. Not evaluated by the FDA.

Documented Research Areas

CJC-1295 (no DAC): GHRH-analog pharmacology and pulsatile release
CJC-1295 (no DAC): GH/IGF-1 axis stimulation in animal models
CJC-1295 (no DAC): Half-life extension via hGRF(1-29) modifications
Ipamorelin: Selective GH secretagogue / ghrelin receptor binding
Ipamorelin: Pulsatile GH release without cortisol or prolactin elevation
Ipamorelin: Longitudinal bone growth research (rodent models)
Ipamorelin: Counteraction of glucocorticoid-induced bone loss

Selected Studies · Peer-Reviewed Literature

A curated list of published peer-reviewed papers indexed in PubMed where CJC-1295 (Modified GRF 1-29) and Ipamorelin have been studied. Provided for research-context only. Linking to the literature does not constitute endorsement of any therapeutic application of either compound or of the blend.

Teichman SL, et al. (2006) · J Clin Endocrinol Metab · CJC-1295 Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults PubMed · 16352683
Jetté L, et al. (2005) · Endocrinology · CJC-1295 Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog PubMed · 15817669
Ionescu M, Frohman LA. (2006) · J Clin Endocrinol Metab · CJC-1295 Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog PubMed · 17018654
Alba M, et al. (2006) · Am J Physiol Endocrinol Metab · CJC-1295 Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse PubMed · 16720630
Raun K, et al. (1998) · Eur J Endocrinol · Ipamorelin Ipamorelin, the first selective growth hormone secretagogue PubMed · 9849822
Andersen NB, et al. (2001) · Bone · Ipamorelin The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats PubMed · 11163462
Lall S, et al. (2001) · J Endocrinol · Ipamorelin Iron-deficiency anaemia and ipamorelin: stimulation of growth hormone secretion in young rats PubMed · 11782339
Sinha DK, et al. (2020) · Transl Androl Urol · Combined Beyond the androgen receptor: the role of growth hormone secretagogues in the modern management of body composition in hypogonadal males PubMed · 32257851

Transparency

Every lot. Every researcher. Same proof.

Each batch ships with a third-party Certificate of Analysis from BioRegen Analytical. HPLC purity, mass-spectrometry identity, sterility, and LAL endotoxin screening. Every test, every lot.

Your lot number ships on the label and on the COA. Enter it in the verifier any time to retrieve the original lab report.

Verify Your Batch Download Sample COA

Certificate of Analysis

BioRegen Analytical · Independent Lab · Lot #21037 · Blend

CompositionCJC-1295 + Ipamorelin

Component ACJC-1295 · 5.04 mg

Component BIpamorelin · 5.02 mg

CJC-1295 Identity (LC-MS)PASS · 1684.5 m/z [M+2H]²⁺

CJC-1295 Purity (HPLC)99.68%

Ipamorelin Identity (LC-MS)PASS · 711.85 m/z

Ipamorelin Purity (HPLC)99.21%

Sterility / LALPASS

Date Tested2026-04-15

Sample · Live data on verifier

Pairs With

Related compounds.

Other research peptides in the Elixser catalog cited alongside the CJC-1295 + Ipamorelin blend in the published research literature.

Adjacent

Tesa + Ipa

5mg / 5mg blend

GHRH analog plus selective GH secretagogue, two complementary points on the somatotrophic axis.

44-AA GHRH analog with DPP-IV-resistant N-terminal modification.

10mg · mitochondrial-derived

Mitochondrial-derived peptide cited in metabolic and AMPK signaling research.

$60

View →

Common Questions

Answered straight.

CJC-1295 with DAC carries a Drug Affinity Complex (DAC) — a maleimide-lysine modification that lets the peptide covalently bind serum albumin, extending its half-life to 6-8 days. CJC-1295 without DAC (also called Modified GRF (1-29) or Mod GRF 1-29) lacks that modification, giving it a much shorter half-life that more closely mimics native GHRH pulsatility. This product is the no-DAC variant. The two are pharmacologically distinct — they should not be substituted for each other in research literature.

Both compounds are tested independently by reverse-phase HPLC and certified at ≥99% per-component purity before blending. The Certificate of Analysis lists the exact lot purity for each peptide separately (most lots run between 99.2% and 99.8%). Mass spectrometry confirms identity for both, and final-blend sterility plus endotoxin testing applies to the combined vial. Your COA ships with the vial and is also retrievable by lot number through our online verifier.

Testing is done by BioRegen Analytical, an independent third-party lab. Every batch of each peptide goes through HPLC purity, LC-MS identity confirmation, sterility screening, and LAL endotoxin testing. The signed Certificate of Analysis ships with each vial. Same lot number, same COA, every time.

Made in the USA. Synthesized in a US cGMP-aligned facility. Tested by a US-based independent lab. Shipped from US fulfillment.

Orders ship via 2-day expedited delivery from US fulfillment. Free over $150. Vials are sealed, packaged with insulation, and shipped in tamper-evident packaging. Tracking number is sent the same day your order leaves the warehouse.

30-day money-back guarantee on every order. If a vial arrives damaged, fails to match the COA, or you change your mind within 30 days, contact us and we will refund or replace. No restocking fees, no return shipping cost on defective product.

One sealed vial containing 5mg CJC-1295 (no DAC) + 5mg Ipamorelin as a combined white powder. Lot-stamped label with both compound identifiers. Signed Certificate of Analysis covering per-component purity and the blended composition. Tamper-evident packaging. Bacteriostatic water for reconstitution research is sold separately and can be added in the cart.

Store sealed at 2-8°C, away from direct light, heat, and moisture. Sealed shelf life is 24 months from the date on the COA. Once reconstituted for research, store reconstituted material refrigerated and follow standard peptide-handling protocols for your lab.

No. All Elixser Peptides products are sold strictly for laboratory research and in vitro study. They are not drugs, food, or cosmetics. They are not for human or veterinary use, consumption, or therapeutic application. They have not been evaluated by the FDA. By purchasing, you agree to use these materials in compliance with applicable laws and ethical research standards.

Research Use Only

CJC-1295 + Ipamorelin

Two compounds. One vial. Full traceability.

Pre-mixed for the bench.

Two compounds, two research records.

Every lot. Every researcher. Same proof.

Related compounds.

Answered straight.

Add the CJC-1295 + Ipamorelin blend to your research arsenal.